Presentation of results for fourth quarter 2011

Presentation of results for fourth quarter 2011 will take place 09:30 (Norwegian time), Tuesday 14 February at Felix Conference Centre, Bryggetorget 3, Aker brygge in Oslo.

The presentation will be available on webcast with the following link:
http://media01.smartcom.no/Microsite/start.aspx?eventid=6605

After the presentation the webcast will be available on demand on the webpage www.diagenic.com under ‘Investor relations’.

Contact:

Erik Christensen, CEO

Telephone: 47 95939918

e-mail: erik.christensen@diagenic.com

About DiaGenic ASA

DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com